CAS No. |
1291074-87-7 |
|---|---|
英文名称 |
(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine (2S,3S)-2,3-dihydroxysuccinate |
别名 |
(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine,L-(+)-Tartaric acid;ENMD-2076 (Tartrate);ENMD-2076 L-(+)-Tartaric acid;ENMD-2076 tartrate (ENMD 2076 |
标准英文名 |
(E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine (2S,3S)-2,3-dihydroxysuccinate |
分子式 |
C25H31N7O6 |
分子量 |
525.57 |
精确分子量 |
525.23 |
SMILES |
CC1=CC(NC2=CC(N3CCN(C)CC3)=NC(/C=C/C3=CC=CC=C3)=N2)=NN1.O=C(O)[C@@H](O)[C@H](O)C(=O)O |
标准SMILES |
CN1CCN(CC1)C1C=C(NC2C=C(C)NN=2)N=C(/C=C/C2C=CC=CC=2)N=1.OC(=O)[C@@H](O)[C@H](O)C(O)=O |
用途 |
ENMD-2076 L-(+)-tartrate is a selective inhibitor of Aurora A and VEGFR (Flt3) with IC50 values of 14 nM and 1.86 nM, respectively; it exhibits 25-fold selectivity for Aurora A over Aurora B and shows weaker activity against VEGFR2/KDR, VEGFR3, FGFR1, FGFR2, and PDGFRα. It demonstrates potent anti-proliferative effects against a broad panel of human solid tumor and hematologic cancer cell lines (IC50: 0.025–0.7 μM), inducing apoptosis and G2/M cell cycle arrest. ENMD-2076 inhibits tumor growth or causes tumor regression in xenograft models derived from breast cancer, colon cancer, melanoma, leukemia, and multiple myeloma. It exhibits significant cytotoxicity against multiple myeloma cell lines (IM9, ARH-77, U266, RPMI8226, MM.1S, MM.1R, NCI-H929) and primary cells (IC50: 2.99–7.06 μM), while showing low cytotoxicity toward hematopoietic progenitor cells. The compound suppresses the PI3K/Akt pathway and downregulates anti-apoptotic proteins survivin and XIAP. In vivo, ENMD-2076 sustains inhibition of FLT3, VEGFR2/KDR, and FGFR1/2 activation in HT29 xenografts; in MDA-MB-231 xenografts, it inhibits angiogenesis and promotes vascular regression. Oral administration of ENMD-2076 at 50, 100, or 200 mg/kg daily significantly suppresses tumor growth in H929 human plasmacytoma xenografts, reduces phosphorylated Histone H3 (pH3), Ki-67, and angiogenesis, and enhances cleaved caspase-3 levels. It is currently in Phase 2 clinical development. |
InChIKey |
KGWWHPZQLVVAPT-PCWHHUEVSA-N |
|
|
评论 |
|---|